PRODUCT TYPES – Page 19

Blend uniformity OOS during multi-product campaign: CAPA aligned to regulatory expectations

The first signs of blend uniformity OOS typically manifest through various signals encountered during routine manufacturing or quality control processes. Key symptoms to observe include:Click to read the full article.

Finished product hardness / friability drift during routine batch release: how to defend specification setting and outlier handling during inspection

Identifying the symptoms of hardness or friability drift starts in the manufacturing or quality control laboratory. Common signals include:Click to read the full article.

Cleaning validation failure after cleaning cycle change: facility and HVAC risk mitigation

Recognizing the symptoms associated with cleaning validation failures is crucial for timely and appropriate response measures. Symptoms may manifest in various ways, including:Click to read the full article.

Biologic subvisible particles OOS during stability pull at 3/6/12 months: investigation strategy aligned to FDA/EMA expectations and comparability principles

The first step in addressing OOS results is to clearly define the symptoms or signals indicating that an issue may exist. Common signals in the lab or production area for…

Cleaning validation failure during CPV review: CAPA aligned to regulatory expectations

Identifying symptoms and signals of cleaning validation failure is the first step in the investigation process. Symptoms may manifest on the production floor or within laboratory settings. Here are some…

Biologic viral clearance validation gap after upstream media/raw material change: patient safety impact assessment and batch disposition governance

Identifying the early signals of a biologic viral clearance validation gap is critical to swift action. Symptoms may manifest as:Click to read the full article.

Biologic cold chain excursion impact during PPQ / process validation: investigation strategy aligned to FDA/EMA expectations and comparability principles

Recognizing early indications of cold chain excursions is essential for timely interventions. Symptoms may manifest as deviations in physical properties, atypical test results, or unusual complaints from stakeholders. Common signals…

Potency variability during multi-product campaign: facility and HVAC risk mitigation

Recognizing the symptoms of potency variability is critical for prompt investigation. Symptoms may include:Click to read the full article.

Biologic host cell protein (HCP) OOS after single-use system supplier change: viral safety and contamination response plan with inspection-ready evidence

Identifying the symptoms or signals that indicate a potential OOS situation is critical for the initial response. In the context of HCP testing following a supplier change in single-use systems,…

Carryover contamination risk during multi-product campaign: CAPA aligned to regulatory expectations

Recognizing early symptoms of carryover contamination is crucial in minimizing its impact. Symptoms may manifest as unexpected changes in product characteristics, such as:Click to read the full article.

Biologic residual DNA OOS during deviation investigation board review: single-use systems risk controls, leachables review, and supplier oversight actions

Identifying symptoms and signals indicative of issues with residual DNA levels in biologics often begins with alerts from routine quality control assays. Common signals include:Click to read the full article.

Stability degradation in hormonal manufacturing: CAPA aligned to regulatory expectations

The first step in addressing stability degradation is recognizing the symptoms that indicate a potential issue. Symptoms can manifest in various forms including:Click to read the full article.